申请人:Vesta Medicines (pty) Ltd.
公开号:US05254572A1
公开(公告)日:1993-10-19
Treatment or prophylaxis of depressed or inadequate intracellular pyridoxal phosphate levels in a human or animal patient resulting from a condition, wherein the pyridoxihe (PN)--pyridoxal phosphate (PLP) pathway is disturbed or insufficient, either by chemical factors as occur in physiological shock myocardial, infarction, release of polyamines or toxins by cell death or microbes, vitamin B6 antagonistic drugs; or by enzymatic insufficiencies inherent in the cells of a patient caused by genetic lack of oxidase or genetic oxidase polymorphism; cellular immaturity of premature infants; in conditions involving anemia, destruction of erythrocytes (e.g. malaria, biliary fever). The deficiencies are counteracted by the administration of pyridoxal or a precursor of pyridoxal which in vivo, once it has entered the bloodstream, is rapidly converted into pyridoxal without the intervention of oxidase or oxygen, optionally and preferably without the intervention of kinase.
治疗或预防由于某种情况导致的人类或动物患者细胞内吡哆醛磷酸水平降低的情况,其中吡哆醇(PN)-吡哆醛磷酸(PLP)途径受到干扰或不足,这种情况可能是由化学因素引起的,如生理性休克心肌梗死、细胞死亡或微生物释放的多胺或毒素、维生素B6拮抗药物;或由患者细胞内固有的酶不足引起的,可能是由于氧化酶的遗传缺乏或基因氧化酶多态性引起的;早产儿的细胞不成熟;在涉及贫血、红细胞破坏(如疟疾、胆热病)的情况下。这些不足可以通过给予吡哆醛或吡哆醇的前体来抵消,一旦进入血液循环,前体会迅速转化为吡哆醛,而不需要氧化酶或氧气的介入,可选择并且最好不需要激酶的介入。